Based on our findings, osimertinib, a potent EGFR inhibitor used for the treatment of patients with metastatic non-small cell lung cancer, significantly reduced the efficacy of SARS-CoV-2 infection. Here, EGFR is linked to non-small cell lung carcinoma.